반응식
[Cl:1][C:2]1[C:3]([C:9]#[N:10])=[N:4][CH:5]=[C:6](Cl)[N:7]=1.[NH2:11][C@@H:12]([C:20]([NH2:22])=[O:21])[CH2:13][C:14]1[CH:19]=[CH:18][CH:17]=[CH:16][CH:15]=1.CCN(C(C)C)C(C)C.O>CN(C=O)C.CCOC(C)=O>[Cl:1][C:2]1[N:7]=[C:6]([NH:11][C@H:12]([CH2:13][C:14]2[CH:19]=[CH:18][CH:17]=[CH:16][CH:15]=2)[C:20]([NH2:22])=[O:21])[CH:5]=[N:4][C:3]=1[C:9]#[N:10]참가 물질
7
실험 절차
A solution of 3,5-dichloropyrazine-2-carbonitrile (86 mg, 0.494 mmol), D-phenylalaninamide (81 mg, 0.494 mmol) and DIEA (0.130 mL, 0.747 mmol) in DMF (2 mL) was stirred at room temperature for 20 h. Water and EtOAc were added. Organic phase was separated, washed with 1N HCl, then with 5% NaHCO3, dried over Na2SO4, concentrated in vacuo to give (R)-2-(6-chloro-5-cyanopyrazin-2-ylamino)-3-phenylpropanamide (128 mg) as an oil.
후처리
- customOrganic phase was separated
- washwashed with 1N HCl
- dry with materialwith 5% NaHCO3, dried over Na2SO4
- concentrationconcentrated in vacuo
출처 및 근거
- ORD 기록
- ord-2957b1622d0d4f708d953c960f099df7
- 출처 데이터셋
- uspto-grants-2016_06
- 특허 번호
- US09359308B2
연결된 노트
불러오는 중…